En Es
Categories

Industry News


Nova Biomedical Launches New Laboratory Blood Glucose Reference Analyzer

By Labmedica International staff writers
19 Nov 2020

Image: Nova Primary analyzer (Photo courtesy of Nova Biomedical)Nova Biomedical (Waltham, MA, USA) has launched Nova Primary, a rapid, accurate, easy to use, blood glucose laboratory analyzer that fills the need for a new glucose reference analyzer to replace the YSI STAT PLUS 2300 Glucose and L-Lactate analyzer from YSI, Inc., (Yellow Springs, OH, USA).

Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI, Inc. is no longer supporting the analyzer, and its discontinuation has left a critical industry void. The Nova Primary analyzer fills that need and will be available for sale in CE regulated countries from January 2021. The Nova Primary was also submitted to the US Food and Drug Administration (FDA) for 510(k) clearance in November 2020 and is anticipated to receive clearance in the first half of 2021.

Similar to the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 10-900 mg/dL. It uses a small, 25 microliter venous whole blood or plasma sample which is internally diluted like the YSI. Results are available in approximately two minutes. Nova Primary’s large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and number of samples remaining, eliminating the need for separate reagent bottles and daily monitoring of their levels. In clinical laboratory studies using venous whole blood and plasma Nova Primary demonstrated excellent correlation to the YSI 2300 and is traceable to NIST glucose standards.




E-mail Print
FaceBook Twitter Google+ Linked in

Nova Biomedical

Nova is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers. Nova’s biosensor technology is incorporated into products ranging from handheld meters for self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes.
Gold member
More info

More articles about Nova Biomedical

25 Jan 2021
Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer
Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
03 Jan 2020
Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler
 Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway, automated sampling, analysis, and feedback control of key cell culture analytes. The FLEX2 measures up to 16 tests, including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More

Additional news

06 Dec 2021
IHF to Launch Geneva Centre of Healthcare Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) is preparing to launch the Geneva Centre of Healthcare Leadership for Sustainability (the Centre) in 2022 in response to the need for hospitals and healthcare services to address climate change.
Read More
06 Dec 2021
Global Mammography Market to Reach USD 3.4 Billion in 2028 Due To Increasing Prevalence of Breast Cancer
The global mammography market is expected to reach USD 3.4 billion in 2028, driven by the increasing prevalence of breast cancer across the globe, rising government fund for ongoing research on breast cancer, and increasing public awareness about cancer. The market growth is being fueled further by increasing number of screening programs and campaigns to create awareness about breast cancer, improving healthcare infrastructure and facilities, and technological advancements in breast imaging techniques.
Read More
03 Dec 2021
Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population
The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests by physicians, low price of tests, and awareness about complications of high diabetes levels.
Read More
02 Dec 2021
Roche Completes Acquisition of TIB Molbiol Group
Roche (Basel, Switzerland) has completed its share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group (Berlin, Germany).
Read More
02 Dec 2021
Siemens Partners with Biotech Company Freenome to Develop Blood Test for Early Breast Cancer Detection
Siemens Healthineers (Erlangen, Germany) and Freenome (South San Francisco, CA, USA) have entered into a collaboration in multiomics and radiomic breast cancer diagnostics to identify suitable markers for early breast cancer detection through blood to augment existing imaging technologies.
Read More
01 Dec 2021
Global Lateral Flow Assay Market to Reach Nearly USD 6.5 Billion by 2031 Due to Surge in Demand for Rapid POC Testing
The global lateral flow assay market is projected to grow at a CAGR of around 5% from USD 3.7 billion in 2020 to over USD 6.4 billion by 2031, driven by the growing adoption of home-based lateral flow assay kits, demand growth of point-of-care testing, and rise in adoption of LFA kits due to their advantages over laboratory tests.
Read More
30 Nov 2021
Global Chemiluminescence Immunoassay (CLIA) Analyzers Market to Surpass USD 7.5 Billion by 2025
The global chemiluminescence immunoassay (CLIA) analyzers market is estimated to grow at a CAGR of 6.4% in the forecast period of 2020-2025 to reach USD 7.6 billion by 2025, with the reagents segment anticipated to capture almost three-fourth of the overall CLIA analyzers market and reach USD 5.7 billion by the end of 2025.
Read More
29 Nov 2021
Global Fluoroscopy Equipment Market to Top USD3.5 Billion by 2031 Due to Demand for Multipurpose Imaging Tools
The global fluoroscopy equipment market is projected to grow at a CAGR of 6% from an estimated USD 1.9 billion in 2021 to surpass USD 3.5 billion by the end of 2031, driven by surging applications of fluoroscopy equipment across various medical fields such as cardiology, nephrology, urology, and others.
Read More
25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions